Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
BMY•Bristol Myers ends partnership for Breyanzi manufacturing scale-up
Bristol Myers Squibb BMY.N has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday.
Bristol Myers determined that Cellares' cell therapy manufacturing platform, Cell Shuttle, could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale, the spokesperson said.
Cellares disputes characterization as sales and prior deal details emerge
Cellares strongly disagrees with this characterization, the company told Reuters. The Cell Shuttle platform has already manufactured a Good Manufacturing Practice-compliant cell therapy product in an FDA-regulated clinical program, it said.
Personalized CAR-T therapies have transformed care for some blood cancer patients, but remain difficult and expensive to produce.
Breyanzi, first approved by the U.S. FDA in 2021, is used to treat lymphoma and other blood cancers. It generated $1.36 billion in sales in 2025.
Endpoints News first reported the development earlier on Tuesday.
Cellares CEO Fabian Gerlinghaus had disclosed the loss of a "large pharmaceutical customer" in a LinkedIn post over the weekend, adding that this will force the company to "resize" its workforce.
Cellares did not respond to a request for comment on the layoffs.
The companies signed a deal in 2024 worth up to $380 million under which Bristol Myers reserved manufacturing capacity across the U.S., the European Union and Japan for CAR-T therapies.
Bristol Myers' decision only applies to Breyanzi and its approved manufacturing process.
